Related Experiment Video
Updated: Sep 1, 2025

Quantitative, Real-time Analysis of Base Excision Repair Activity in Cell Lysates Utilizing Lesion-specific Molecular Beacons
Published on: August 6, 2012
Taking the Road Less Traveled: Following Molecular Trail Markers
Ana C Veneziani1, Amit M Oza1,2,3
1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Abstract:
Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.
Insights
Targeted therapy for low-grade serous ovarian carcinoma is limited. Molecular characterization reveals genetic alterations linked to outcomes, paving the way for new targeted treatments.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Low-grade serous ovarian carcinoma (LGSC) presents a significant unmet need for effective targeted therapies.
- Current treatment options for LGSC are limited, highlighting the necessity for novel therapeutic strategies.
Purpose of the Study:
- To review recent advances in the molecular characterization of LGSC.
- To highlight the association between genetic alterations and clinical outcomes in LGSC.
- To explore the potential for novel targeted therapies based on these findings.
Main Methods:
- Review of recent scientific literature and molecular profiling studies.
- Analysis of genetic alterations in LGSC.
- Correlation of genetic findings with clinical outcomes.
Main Results:
- Recent molecular characterization studies have identified key genetic alterations in LGSC.
- These genetic alterations show a significant association with patient clinical outcomes.
- This understanding broadens the possibilities for developing new targeted therapies.
Conclusions:
- Advances in molecular characterization are transforming the therapeutic landscape for LGSC.
- Identifying specific genetic alterations provides a foundation for precision medicine approaches.
- Novel targeted therapies hold promise for improving outcomes in LGSC patients.
Related Concept Videos
Modern Molecular Taxonomy
Applications of Molecular Taxonomy
Sanger Sequencing

